Comparative Pharmacology
Head-to-head clinical analysis: CAFCIT versus CAFFEINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAFCIT versus CAFFEINE CITRATE.
CAFCIT vs CAFFEINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Caffeine citrate is a central nervous system stimulant. It competitively blocks adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and release of neurotransmitters such as dopamine and norepinephrine. In neonates, it stimulates respiratory centers, increases minute ventilation, and improves sensitivity to hypercapnia.
Caffeine is a methylxanthine that acts as a central nervous system stimulant. It competitively antagonizes adenosine receptors (A1 and A2A subtypes), leading to increased neuronal firing and neurotransmitter release. It also inhibits phosphodiesterase, resulting in elevated intracellular cAMP levels, and enhances calcium release from sarcoplasmic reticulum in muscle cells, promoting contractility.
Caffeine citrate: IV or PO, loading dose 20 mg/kg (caffeine base) once, then maintenance 5 mg/kg (caffeine base) once daily. Onset of action: 15-30 minutes IV; peak effect: 30-120 minutes. Duration: 40-100 hours.
20 mg/kg caffeine citrate (equivalent to 10 mg/kg caffeine base) IV over 30 minutes as a single loading dose, followed by a maintenance dose of 5-10 mg/kg caffeine citrate (2.5-5 mg/kg caffeine base) IV once daily, starting 24 hours after the loading dose.
None Documented
None Documented
Terminal elimination half-life: In neonates (postmenstrual age 28-44 weeks), 40-230 hours (mean ~100 hours); in adults, 3-6 hours. Clinical context: Prolonged in preterm neonates due to immature hepatic function.
Adults: 3-6 hours (mean 5 hours). Neonates: 40-230 hours (mean 80 hours) due to immature hepatic clearance; clinical context: prolonged half-life in preterm infants requires dosing interval adjustment (usually 24 hours).
Renal: approximately 86% as unchanged drug and metabolites (paraxanthine, theophylline, theobromine) with about 1% unchanged; biliary/fecal: negligible.
Renal excretion (86% as unchanged drug and metabolites; 1% as caffeine, 85% as paraxanthine and other metabolites). Fecal excretion is minimal (<2%).
Category C
Category C
Respiratory Stimulant (Xanthine)
Respiratory Stimulant (Xanthine)